China has been reeling under a spate of medical disasters, with last month’s vaccine fiasco followed by the most recent case of carcinogens found in heart medicines that were manufactured by a national pharmaceutical company. The government put out a report highlighting this grave issue. The medicines in question contained Valsartan as an ingredient, which is used for treatment of high blood pressure as well as preventing heart failure. The drug was in news in early July, when a recall was ordered from North America andEurope, after certain batches were discovered containing N-nitrosodimethylamine, a potent carcinogen.
The company in question, Zhejiang Huahai Pharmaceuticals, is located in Eastern China’s Linhai, which notified the authorities when they discovered the problem. The company put out a statement, where it said that it put out a recall notice in China as well as overseas on July 13, and that the entire material with regards to China’s market was recalled by the July 23. The company pulled out all the concerned products from the American pharmacies, one of their largest markets, on the July 16. The Chinese FDA stated that a screening concerning the country’s Valsartan ingredient suppliers had been conducted. The shocking news comes at a time when the country is still reeling from the shock concerning the use of faulty diphtheria and tetanus vaccines for children, which amounted to around quarter of a million doses throughout the country. The recent incident may however, lower the people’s belief in the countries medical system even further.
The ill-effects of Valsartan may also hit some people in the US city of Idaho, as hundreds of residents are reported to have consumed the medication that has since been started to be taaken off the shelves by the US FDA. The brands that are being recalled by the authorities include those manufactured by Solco Healthcare, Teva Pharmaceuticals Industries Ltd. and Major Pharmaceuticals. Certain other companies also use drugs containing Valsartan, however they don’t have similar impurities plaguing other companies.